HEK293-CTLA4

Disclaimer: The prices displayed for cell lines are exclusively for not-for-profit customers. If you represent a commercial entity, please contact us for alternative pricing.The HEK293-CTLA4 cell line is a stable recombinant HEK293 cell line engineered to express the CTLA4 receptor at a medium-low level, approximately 4,000 molecules per cell.

This cell line was developed using inscreenex's landing pad technology, ensuring precise and reproducible integration of the CTLA4 gene at a specific, pre-validated genomic locus. CTLA4, also known as CD152, is an immune checkpoint protein that plays a crucial role in regulating T-cell activation. By competing with the stimulatory receptor CD28 for binding to B7 molecules (CD80 and CD86) on antigen-presenting cells, CTLA4 downregulates immune responses, thus maintaining self-tolerance and preventing autoimmunity. CTLA4 is a key target in cancer immunotherapy, particularly for drugs like ipilimumab, which aim to enhance anti-tumor immunity by blocking this checkpoint and activating T cells.The expression of CTLA4 in this cell line was confirmed using flow cytometry with a target-specific antibody, ensuring reliable and consistent receptor density across the cell population.